CompanyGraph
CK Life Sciences Int'l.,
0775 · HKEX · Hong Kong
Price data from its LSI listing on XSTU, quoted in EUR
ck-lifesciences.comFinancials as of FY2025
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $703.77M, above the global median of $520.53M
- PositionCurrent ratio is 0.91×, lower than 95% of its Biotechnology peers (median 5.5×)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
8.27BHKD1.05B · vs all stocks (USD)
Revenue (TTM)
5.52BHKD703.77M · vs all stocks (USD)
Profit Margin
-1.17%vs Biotechnology peers
Beta
0.4550xvs all stocks
52-Week Change
-43.81%vs all stocks
Market Capitalization
8.27BHKD1.05B · vs all stocks (USD)
Enterprise Value
11.73BHKD1.49B · vs all stocks (USD)
Price to Sales (TTM)
0.9489xvs Biotechnology peers
Price to Book (MRQ)
1.32xvs Biotechnology peers
Enterprise to Revenue
2.12xvs Biotechnology peers
Enterprise to EBITDA
60.40xvs Biotechnology peers
Profit Margin
-1.17%vs Biotechnology peers
Operating Margin
3.17%vs Biotechnology peers
Return on Assets (TTM)
-0.06%vs Biotechnology peers
Return on Equity (TTM)
-2.23%vs Biotechnology peers
Revenue (TTM)
5.52BHKD703.77M · vs all stocks (USD)
Revenue per Share (TTM)
0.5740HKDUpdated Aug 19, 2026Quarterly Revenue Growth
4.20%vs Biotechnology peers
Gross Profit (TTM)
1.55BHKD197.33M · vs all stocks (USD)
EBITDA (TTM)
194.14MHKD24.75M · vs all stocks (USD)
Net Income (TTM)
-64.70MHKD-8.25M · vs all stocks (USD)
Operating Cash Flow (TTM)
143.00MHKD18.23M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-377.95MHKD-48.18M · vs all stocks (USD)
5-Year Average Dividend Yield
1.43%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
66.46MHKDFY2025 · Dec 31, 2025Revenue
5.41BHKDFY2025 · Dec 31, 2025Cost of Goods Sold
3.83BHKDFY2025 · Dec 31, 2025Gross Profit
1.58BHKDFY2025 · Dec 31, 2025Operating Income
-131.03MHKD-16.70M · vs all stocks (USD)
Pre-tax Income
-18.01MHKDFY2025 · Dec 31, 2025Income Tax Expense
170.44MHKDFY2025 · Dec 31, 2025Net Income
-188.45MHKDFY2025 · Dec 31, 2025EBIT
248.88MHKDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-139.82MHKDFY2025 · Dec 31, 2025Selling, General & Administrative
185.39MHKDFY2025 · Dec 31, 2025Other Operating Expenses
731.02MHKDFY2025 · Dec 31, 2025Non-operating Interest Income
21.20MHKDFY2025 · Dec 31, 2025Non-operating Interest Expense
266.89MHKDFY2025 · Dec 31, 2025EPS (Basic)
-0.0194HKDFY2025 · Dec 31, 2025EPS (Diluted)
-0.0194HKDFY2025 · Dec 31, 2025Basic Shares Outstanding
9.61BSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
9.61BSharesFY2025 · Dec 31, 2025Minority Interests (P&L)
1.64MHKDFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00HKDFY2025 · Dec 31, 2025Operating Cash Flow
69.28MHKDFY2025 · Dec 31, 2025Free Cash Flow
-73.82MHKDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
603.07MHKDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-18.01MHKDFY2025 · Dec 31, 2025Other Non-cash Items
245.57MHKDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-31.88MHKDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-126.40MHKDFY2025 · Dec 31, 2025Capital Expenditures
-143.10MHKDFY2025 · Dec 31, 2025Net Intangibles (CF)
2.35MHKDFY2025 · Dec 31, 2025Net Acquisitions
30.00MHKDFY2025 · Dec 31, 2025Purchase of Investments
-195.00MHKDFY2025 · Dec 31, 2025Sale of Investments
17.90MHKDFY2025 · Dec 31, 2025Net Investing Cash Flow
-290.20MHKDFY2025 · Dec 31, 2025Long-term Debt Issuance
2.11BHKDFY2025 · Dec 31, 2025Long-term Debt Payments
-1.57BHKDFY2025 · Dec 31, 2025Other Financing Charges
1.64MHKDFY2025 · Dec 31, 2025Net Financing Cash Flow
538.31MHKDFY2025 · Dec 31, 2025Shares Outstanding
9.61BSharesUpdated Aug 19, 2026Float Shares
2.40BSharesUpdated Aug 19, 2026% Held by Insiders
74.98%vs all stocks
% Held by Institutions
0.72%vs all stocks
Total Cash (MRQ)
535.66MHKD68.29M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.0560HKDUpdated Aug 19, 2026Total Debt (MRQ)
6.83BHKD871.00M · vs all stocks (USD)
Total Debt to Equity (MRQ)
1.67xvs Biotechnology peers
Current Ratio (MRQ)
0.9140xvs Biotechnology peers
Book Value per Share (MRQ)
0.4120HKDUpdated Aug 19, 2026Total Assets
11.84BHKD1.51B · vs all stocks (USD)
Total Current Assets
3.01BHKDFY2025 · Dec 31, 2025Total Liabilities
7.99BHKDFY2025 · Dec 31, 2025Total Non-current Assets
8.83BHKDFY2025 · Dec 31, 2025Total Non-current Liabilities
4.52BHKDFY2025 · Dec 31, 2025Total Current Liabilities
3.47BHKDFY2025 · Dec 31, 2025Cash & Cash Equivalents
603.07MHKDFY2025 · Dec 31, 2025Accounts Receivable
966.80MHKDFY2025 · Dec 31, 2025Inventory
1.23BHKDFY2025 · Dec 31, 2025Accounts Payable
373.04MHKDFY2025 · Dec 31, 2025Short-term Debt
2.45BHKDFY2025 · Dec 31, 2025Long-term Debt
4.17BHKDFY2025 · Dec 31, 2025Common Stock (Book)
961.11MHKDFY2025 · Dec 31, 2025Retained Earnings
1.97BHKDFY2025 · Dec 31, 2025Total Shareholders' Equity
3.85BHKD490.34M · vs all stocks (USD)
52-Week Low
0.5300HKDUpdated Aug 19, 202652-Week High
1.08HKDUpdated Aug 19, 202652-Week Change
-43.81%vs all stocks
Beta
0.4550xvs all stocks
50-Day MA
0.5950HKDUpdated Aug 19, 2026200-Day MA
0.7457HKDUpdated Aug 19, 2026Avg 10-Day Volume
4.20MSharesUpdated Aug 19, 2026Avg 30-Day Volume
2.94MSharesUpdated Aug 19, 2026Diluted EPS (TTM)
-0.0100HKDUpdated Aug 19, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 0.91×, lower than 95% of its Biotechnology peers (median 5.5×)Significant
Current ratio: 0.91Industry median: 5.50Industry P5: 0.97Peers compared: 197
Price-to-book is 1.32×, lower than 95% of its Biotechnology peers (median 5.36×)Notable
Price-to-book: 1.32Industry median: 5.36Industry P5: 1.40Peers compared: 197
Financial Health
Altman Z-Score 1.33: grey zoneSignificant
Altman Z-Score: 1.33
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $703.77M, above the global median of $520.53MNotable
Revenue (USD): 703,767,385.108Global Median: 520,528,949.311
Companies that share the same coordination system — how they create, deliver, or capture value.
Blue Jet Healthcare Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Cronos Group Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Suzhou Highfine Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhejiang Ausun Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Eis Eczacıbaşı İlaç ve Sanayi A.Ş.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hainan Haiyao Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Guangxi Wuzhou Zhongheng Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
KPC Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Novogene Co., Ltd.
Tier 1ProductionApproval-Gated PipelineSenseMakingFlow
SSY Group Limited
Tier 1ProductionApproval-Gated PipelineRuleFlow